CTOs on the Move

Oxis International

www.oxis.com

 
Oxis International, Inc. has formed and provided initial financing to support the activities of its wholly owned subsidiary, Oxis Biotech, Inc. The parent company, Oxis International is engaged in the research, development and sale of products to counteract oxidative stress and inflammation. Oxis Biotech is focused on the acquisition of cannabis related intellectual properties and commercialization of therapies developed from the intellectual properties to treat certain diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oxis.com
  • 468 N Camden Dr
    Beverly Hills, CA USA 90210
  • Phone: 650.212.2568

Executives

Name Title Contact Details

Similar Companies

Human Care Systems, Inc.

HCS designs and delivers technology driven therapy management to improve patient initiation, adherence, and persistence. Since 2008, HCS has worked with biopharma brand teams who want to deliver personalized, omni-channel programming with measured outcomes.

Medsite

Medsite is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

Acura Pharmaceuticals

Acura Pharmaceuticals is a Palatine, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.